Michael Graves - 27 Oct 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Reporting relationship: Director
Issuer ticker: EGRX
Reported as of: 27 Oct 2023
Net transaction value: +$46,238
SEC form: 4
Accepted by SEC: 31 Oct 2023, 17:41:24 UTC
Prior SEC filing: 09 Mar 2023
Next SEC filing: 22 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Scott Tarriff, Attorney-in-Fact

Key filing fact

Michael Graves filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 31 Oct 2023.

Key facts

This page summarizes Michael Graves's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Oct 2023, 17:41.

Change

Previous filing in this sequence was filed on 09 Mar 2023.
Current net transaction value: +$46,238.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EGRX transaction

Common Stock

Options Exercise

Transaction value: $46,238
Shares: +9,360
Change %: +936%
Price: $4.94
Shares after: 10,360
Date: 27 Oct 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EGRX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -9,360
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Oct 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,360
Exercise price: $4.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .